Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Diffuse Large B Cell Lymphoma
Drug:
carboplatin
(
Tubulin polymerization promoter
) +
gemcitabine
(
DNA synthesis inhibitor
) +
dexamethasone
(
GCR agonist
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
01/20/2021
Excerpt:
Diffuse large B-Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Preferred Regimens…GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab or (gemcitabine, dexamethasone, carboplatin) ± rituximab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login